Lowest-Rated StocksLowest-RatedNASDAQ:IGMS IGM Biosciences (IGMS) Stock Price, News & Analysis $1.31 +0.04 (+3.15%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.28 -0.03 (-2.29%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About IGM Biosciences Stock (NASDAQ:IGMS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IGM Biosciences alerts:Sign Up Key Stats Today's Range$1.28▼$1.3350-Day Range$1.08▼$1.3652-Week Range$0.92▼$22.50Volume487,358 shsAverage Volume545,486 shsMarket Capitalization$78.76 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingReduce Company Overview IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Read More IGM Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreIGMS MarketRank™: IGM Biosciences scored higher than 85% of companies evaluated by MarketBeat, and ranked 140th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingIGM Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.90, and is based on no buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageIGM Biosciences has received no research coverage in the past 90 days.Read more about IGM Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for IGM Biosciences are expected to grow in the coming year, from ($3.35) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGM Biosciences is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGM Biosciences is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGM Biosciences has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about IGM Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.42% of the float of IGM Biosciences has been sold short.Short Interest Ratio / Days to CoverIGM Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IGM Biosciences has recently increased by 2.79%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIGM Biosciences does not currently pay a dividend.Dividend GrowthIGM Biosciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.08 Percentage of Shares Shorted2.42% of the float of IGM Biosciences has been sold short.Short Interest Ratio / Days to CoverIGM Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IGM Biosciences has recently increased by 2.79%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment1.38 News SentimentIGM Biosciences has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for IGM Biosciences this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, IGM Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,494.00 in company stock.Percentage Held by Insiders57.00% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IGM Biosciences' insider trading history. Receive IGMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address IGMS Stock News HeadlinesIGM Biosciences, Inc. (NASDAQ:IGMS) CFO Sells $11,101.07 in StockJuly 26, 2025 | insidertrades.comAnalysts Set IGM Biosciences, Inc. (NASDAQ:IGMS) PT at $5.50July 23, 2025 | americanbankingnews.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 2 at 2:00 AM | Brownstone Research (Ad)IGM Biosciences Enters Definitive Merger Agreement with Concentra Biosciences for Acquisition - NasdaqJuly 3, 2025 | nasdaq.comIGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right - Seeking AlphaJuly 3, 2025 | seekingalpha.comIGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders - MorningstarJuly 3, 2025 | morningstar.comMIGM Biosciences Shares Surge on Takeover Agreement with ConcentraJuly 2, 2025 | msn.comIGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to ShareholdersJuly 1, 2025 | businesswire.comSee More Headlines IGMS Stock Analysis - Frequently Asked Questions How have IGMS shares performed this year? IGM Biosciences' stock was trading at $6.11 at the beginning of the year. Since then, IGMS shares have decreased by 78.6% and is now trading at $1.31. How were IGM Biosciences' earnings last quarter? IGM Biosciences, Inc. (NASDAQ:IGMS) announced its earnings results on Thursday, July, 31st. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of ($0.30) by $1.88. The firm earned $143.62 million during the quarter, compared to analysts' expectations of $3.20 million. IGM Biosciences had a negative trailing twelve-month return on equity of 125.30% and a negative net margin of 36.81%. When did IGM Biosciences IPO? IGM Biosciences (IGMS) raised $125 million in an initial public offering on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of IGM Biosciences? Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IGM Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGM Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings7/31/2025Today8/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IGMS CIK1496323 Webigmbio.com Phone650-965-7873FaxN/AEmployees190Year Founded2010Price Target and Rating Average Price Target for IGM Biosciences$5.50 High Price Target$20.00 Low Price Target$1.50 Potential Upside/Downside+319.8%Consensus RatingReduce Rating Score (0-4)1.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$195.79 million Net Margins-36.81% Pretax Margin-7,417.79% Return on Equity-125.30% Return on Assets-20.61% Debt Debt-to-Equity RatioN/A Current Ratio5.71 Quick Ratio5.71 Sales & Book Value Annual Sales$2.68 million Price / Sales29.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book1.60Miscellaneous Outstanding Shares60,120,000Free Float25,849,000Market Cap$78.76 million OptionableOptionable Beta0.60 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IGMS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.